A recently completed analysis of survival data from the 2 large phase III ixabepilone trials in MBC demonstrated a trend towards increased OS that did not reach statistical significance. 59 However, an OS benefit was reported in patients treated with ixabepilone following a pre-defined Cox Regression analysis with data adjusted according to prognostic factors. 60 A number of ongoing trials are evaluating ixabepilone in combination with other chemotherapeutic and biologic agents for treatment of a variety of tumor types.
← all excerpts
Management of advanced breast cancer with the epothilone B analog, ixabepilone.
1
—
—